financetom
Business
financetom
/
Business
/
Levi Strauss Seen Improving Organic Revenue Growth Profile With Dockers Sale, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Levi Strauss Seen Improving Organic Revenue Growth Profile With Dockers Sale, UBS Says
May 26, 2025 11:42 AM

09:55 AM EDT, 05/21/2025 (MT Newswires) -- Levi Strauss' (LEVI) pending divestiture of its Dockers brand will allow the company to improve its organic revenue growth profile, UBS Securities said in a note Tuesday.

The sale will also enable Levi Strauss to generate higher margins by reducing its cost structure, further cut its US wholesale exposure and simplify its business to focus on the core Levi's brand and Beyond Yoga business, the firm said.

The deal, expected to close around July 31 for Dockers' US and Canada businesses and around Jan. 31 next year for remaining operations, will also enable Levi Strauss to go ahead with incremental share repurchases, UBS said.

UBS said its earnings-per-share forecast for 2025 is largely unchanged after accounting for the incremental $100 million in share buybacks.

UBS maintained the company's buy rating and $20 price target.

Price: 17.58, Change: -0.27, Percent Change: -1.49

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
LifeMD to offer Novo's Ozempic at $499 a month to eligible US cash-paying customers
LifeMD to offer Novo's Ozempic at $499 a month to eligible US cash-paying customers
Sep 30, 2025
Sept 30 (Reuters) - Telehealth firm LifeMD ( LFMD ) said on Tuesday it would partner with Novo Nordisk to offer its diabetes drug Ozempic at $499 per month to eligible U.S. patients, including insured people whose plans do not cover GLP-1 therapies. Novo offers Ozempic for $499 a month to eligible cash-paying patients via its own pharmacy, NovoCare, and...
Cerence to Build In-Car Assistant for Suzuki's eVitara Battery Electric Vehicle
Cerence to Build In-Car Assistant for Suzuki's eVitara Battery Electric Vehicle
Sep 30, 2025
08:29 AM EDT, 09/30/2025 (MT Newswires) -- Cerence ( CRNC ) said Tuesday that it is collaborating with Suzuki Motor to build an in-car assistant for Suzuki's first battery electric vehicle model called eVitara. The company said it will use its conversational artificial intelligence technology to build Cerence Assistant, which will allow users to control vehicle functions like air conditioning...
BTC Development Corp. Announces Pricing of $220,000,000 Initial Public Offering
BTC Development Corp. Announces Pricing of $220,000,000 Initial Public Offering
Sep 30, 2025
PHILADELPHIA, PA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- BTC Development Corp (the “Company”) today announced the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The Company’s units will be listed on the Nasdaq Global Market under the symbol “BDCIU” and will begin trading on September 30, 2025. Each unit issued in the...
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
Sep 30, 2025
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( ARTL ) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved